Effect of apolipoprotein E polymorphism on statin-induced decreases in plasma lipids and cardiovascular events
-
Jaroslav A. Hubacek
and
Michal Vrablik
Abstract
Hypercholesterolemia or dyslipidemia is an independent risk factor for cardiovascular disease and statins (inhibitors of a key enzyme of cholesterol synthesis, 3-hydroxymethyl glutaryl coenzyme A reductase) are the drugs of choice for decreasing plasma cholesterol. It has been estimated that genetic factors can explain 40%–60% of final cholesterol concentrations and approximately 70% of the efficacy of statin treatment. The gene most often analyzed in the context of statin efficacy is the gene for apolipoprotein E (APOE). This review summarizes evidence of the association between variations in the APOEgene locus and the response of plasma lipids to statin therapy. Although the results are not consistent, carriers of the APOE4allele seems to be less responsive to statins than carriers of APOE2and APOE3alleles. This effect is partially context-dependent (gene-gender interactions; gene-nutrition and gene-smoking interactions have not yet been studied) and the absolute differences vary between different population groups.
©2011 by Walter de Gruyter Berlin New York
Articles in the same Issue
- Editorial
- Pharmacogenomics and drug interactions. A specific journal
- Publisher's Note
- Publisher's Note
- Reviews
- Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine
- Effect of apolipoprotein E polymorphism on statin-induced decreases in plasma lipids and cardiovascular events
- Minireview
- Potential role of multidrug resistant proteins in refractory epilepsy and antiepileptic drugs interactions
- Original Article
- Biological and genetic factors associated with ABCB1 and pregnane-X-receptor expressions in peripheral blood mononuclear cells in the STANISLAS cohort
- Short Communications
- ABCA1 and ABCG1 expressions are regulated by statins and ezetimibe in Caco-2 cells
- Tumor necrosis factor-α and interleukin-6 expression in leukocytes and their association with polymorphisms and bone markers in diabetic individuals treated with pioglitazone
- Short Report
- From systems biology and functional genomics to personalized health
Articles in the same Issue
- Editorial
- Pharmacogenomics and drug interactions. A specific journal
- Publisher's Note
- Publisher's Note
- Reviews
- Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine
- Effect of apolipoprotein E polymorphism on statin-induced decreases in plasma lipids and cardiovascular events
- Minireview
- Potential role of multidrug resistant proteins in refractory epilepsy and antiepileptic drugs interactions
- Original Article
- Biological and genetic factors associated with ABCB1 and pregnane-X-receptor expressions in peripheral blood mononuclear cells in the STANISLAS cohort
- Short Communications
- ABCA1 and ABCG1 expressions are regulated by statins and ezetimibe in Caco-2 cells
- Tumor necrosis factor-α and interleukin-6 expression in leukocytes and their association with polymorphisms and bone markers in diabetic individuals treated with pioglitazone
- Short Report
- From systems biology and functional genomics to personalized health
